Showing 4641-4650 of 5771 results for "".
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Plex Pharmaceuticals Awarded $1.6 Million in Grant Funding from NIH to Advance Eye Drop Therapy for Cataractshttps://modernod.com/news/plex-pharmaceuticals-awarded-1-6-million-in-grant-funding-from-nih-to-advance-eye-drop-therapy-for-cataracts/2477987/Plex Pharmaceuticals announced that it has been awarded two Small Business Innovation Research grants from the National Institutes of Health (NIH) National Eye Institute: a $1.3 million phase 2 grant (R44EY027236) and a $300,000 phase 1
- Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenavahttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-for-norse-2-study-of-lytenava/2477982/Outlook Therapeutics announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. “We are extremely grateful to the patients and medical staff
- Ocutrx Says It Will Deliver World’s First 5G AR/XR Medical Specific Platform in 2021https://modernod.com/news/ocutrx-says-it-will-deliver-worlds-first-5g-ar-xr-medical-specific-platform-in-2021/2477980/Ocutrx Vision Technologies announced plans to deliver the first AR headsets specific for medical applications providing connectivity from AT&T and using 5G products from Qualcomm Technologies. Ocutrx is building its AR/XR medical device, the Oculenz headset, for patient use; and a seco
- Apple Was Already Developing Handwashing Sensing Before COVID-19 Hithttps://modernod.com/news/apple-was-already-developing-handwashing-sensing-before-covid-19-hit/2477981/When Apple vice president of technology Kevin Lynch announced at WWDC last week that Apple Watch would add an automatic handwashing-detection feature in its next update, many people naturally assumed the feature was prompted by the COVID-19 pandemic – a public health emergency that has strongly u
- STAAR Surgical’s EVO Viva Presbyopia Correcting Lens Receives CE Mark Approvalhttps://modernod.com/news/staar-surgicals-evo-viva-presbyopia-correcting-lens-receives-ce-mark-approval/2477977/STAAR Surgical announced that its EVO Viva presbyopia correcting implantable collamer lens (ICL) has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva,” from its European Noti
- Apellis Completes Enrollment in Two Phase 3 Studies of Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-completes-enrollment-in-two-phase-3-studies-of-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2477978/Apellis Pharmaceuticals announced that it completed enrollment in the phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan (APL-2), a targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA causes blind
- Regeneron Advances Double Antibody Cocktail Into Phase 3 COVID-19 Prevention Studyhttps://modernod.com/news/regeneron-kicks-off-prevention-trial-for-covid-19-antibody-cocktail/2477979/Regeneron Pharmaceuticals announced the start of a phase 3 study investigating the ability of the double antibody cocktail REGN-COV2 to prevent infection among uninfected people who have had close exposure to a COVID-19 patient, according to a FirstWord Pharma report. The company added that REGN-
- VisionCare Names Thomas Ruggia as New Chief Executive Officerhttps://modernod.com/news/visioncare-names-thomas-ruggia-as-new-chief-executive-officer/2477973/VisionCare announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020. VisionCare provides the only FDA approved surgical treatment for macular degeneration, the telescope implant and CentraSight treatment program. “We’re thrilled
- Patrick F. Williams Appointed Chief Financial Officer of Staar Surgicalhttps://modernod.com/news/patrick-f-williams-appointed-chief-financial-officer-of-staar-surgical/2477969/Staar Surgical announced that Patrick F. Williams has joined the company as Chief Financial Officer, effective today. Mr. Williams is reporting to Caren Mason, President and Chief Executive Officer. His appointment is part of a planned transition following Deborah Andrews’ previously announced re